The new analysis included 19,134 of these patients and showed that there were 19% fewer deaths in patients initiated on NOACs compared to VKAs at the time of AF diagnosis.
Patients with atrial fibrillation who have ≥1 non-sex CHA2DS2VASc stroke risk factor should receive oral anticoagulation as antithrombotic therapy.
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
Patients with atrial fibrillation who take NSAIDs in addition to oral anticoagulants may have an increased risk for major bleeding and stroke.
Apixaban demonstrated superiority over warfarin in terms of reducing the risk for major bleeding in patients with atrial fibrillation and end-stage kidney disease who were on dialysis.
Apixaban reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin.
Dabigatran may be associated with a risk reduction of major vascular complications in patients who develop a myocardial injury after noncardiac surgery.
For this study, researchers searched several large databases (from 1980 to 2016) for randomized, controlled trials (RCTs) that compared clinical outcomes in patients on DAPT taking PPIs or H2RAs.
Troponin-T, N-terminal pro-B-type natriuretic peptide, and growth differentiation factor-15 may offer prognostic utility on mortality and bleeding events in patients with atrial fibrillation who receive anticoagulation.
Patients treated for acute pulmonary embolism with direct oral anticoagulants at doses against manufacturer recommendations had a higher rate of major bleeding events.
Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients.
A decision-making algorithm on venous thromboembolism prophylaxis was developed by the Association of Paediatric Anaesthetists of Great Britain and Ireland.
The system is intended for properly selected trained users ≥22 years of age who have been stabilized on anticoagulation with vitamin K antagonists for ≥6 weeks.
A greater burden of atrial fibrillation or flutter in patients with paroxysmal atrial fibrillation was associated with a higher risk for stroke when not taking anticoagulants.
Reduced doses be as effective as full-dose direct oral anticoagulants for extended-duration venous thromboembolism treatment.
Similar number of out-of-range next INR values were seen in patients with and without extended testing interval.
Amneal's generic product is available in a 5mg strength tablet supplied in 100-count bottles.
Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.
Anxiety may increase the risk for ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation.
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
Extended prophylaxis with aspirin does not differ significantly from rivaroxaban for venous thromboembolism prevention in patients who have undergone total hip or knee arthroplasty.
Using digital adherence devices to improve medication adherence in patients with atrial fibrillation may reduce the rate of ischemic strokes.
Anticoagulants are associated with increased risk for ischemic stroke and hemorrhage in older patients with chronic kidney disease and a new diagnosis of atrial fibrillation.
A 45-year-old man presents to the emergency department with some mental confusion and near syncope.
Treatment with direct oral anticoagulants in addition to antiplatelet therapy appears efficacious for patients with STEMI.
A 35-year-old pregnant woman presents to the emergency department with progressive dyspnea and palpitations that have worsened during the last 3 weeks.
Clinical practice guidelines for anticoagulation therapy for cardiopulmonary bypass have been developed.
Cost-effective DOACs like apixaban prevent strokes better than warfarin in patients with atrial fibrillation.
Bleeding Risk, Stroke Outcomes With Edoxaban vs Enoxaparin-Warfarin for Cardioversion of Atrial FibrillationDecember 15, 2017
In patients with atrial fibrillation at high risk for stroke, edoxaban is associated with lower rates of cardiovascular death events.
Triple therapy is associated with increased mortality risk in patients with LGIB and CAD.
The Cardiology Advisor Articles
- Class 1 Device Recall: Endologix AFX Device Recalled Due to Type III Endoleaks
- Harvard: Fraudulent Data Found in Publications of Heart Researcher
- Traumatic Life Events May Increase Risk for Atrial Fibrillation in Older Women
- No Differences Between Bivalirudin, UFH Post-PCI After Ticagrelor Pretreatment
- Rivaroxaban Approved to Reduce Risk of Major Cardiovascular Events in CAD, PAD
- Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy
- Long-Term Exposure to Elevated BP Associated With AS and AR
- Risk Factors for Atherosclerotic Cardiovascular Disease in the South Asian Population
- Takotsubo Syndrome Associated With Substantial Morbidity, Mortality
- Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D
- Metformin May Improve Vascular Health in Adolescents With Type 1 Diabetes
- Improved Cardiovascular Event Reporting Needed in Leukemia Clinical Trials
- Psoriasis Associated With Clinical Signs of Accelerated Atherosclerosis
- Can Dermatoscope Magnets Be Used With CV Implanted Electronic Devices?
- The Striking Effects of Diversity in Health Care: Improving Patient Outcomes